Labcorp (LH)
(Delayed Data from NYSE)
$198.40 USD
+0.05 (0.03%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $198.28 -0.12 (-0.06%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LH 198.40 +0.05(0.03%)
Will LH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for LH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LH
Integer Holdings (ITGR) Q1 Earnings Top Estimates, Margins Up
3 Medical Products Stocks Set to Beat This Earnings Season
LH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View
Compared to Estimates, Labcorp (LH) Q1 Earnings: A Look at Key Metrics
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
Other News for LH
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Laboratory (LH), Fusion Pharmaceuticals (FUSN) and Integer Holdings (ITGR)
Labcorp price target lowered by $11 at Baird, here's why
Labcorp price target lowered by $21 at Barclays, here's why
Weitz Conservative Allocation Fund Q1 2024 Commentary
Weitz Multi Cap Equity Fund Q1 2024 Commentary